Go Pro
→ Major Buy Alert Issued for September 30th (From TradeSmith) (Ad)tc pixel Free SCPS Stock Alerts

Scopus BioPharma (SCPS) Competitors

Scopus BioPharma logo
$0.0004 0.00 (0.00%)
As of 09/23/2026 10:24 AM Eastern
Compare

SCPS vs. VINC, CARM, VRPX, SYRS, and TRVN

Should you buy Scopus BioPharma stock or one of its competitors? Scopus BioPharma's main competitors and comparable companies include Vincerx Pharma (VINC), Carisma Therapeutics (CARM), Virpax Pharmaceuticals (VRPX), Syros Pharmaceuticals (SYRS), and Trevena (TRVN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Scopus BioPharma compare to Vincerx Pharma?

Vincerx Pharma (NASDAQ:VINC) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends and media sentiment.

44.0% of Vincerx Pharma shares are held by institutional investors. 15.6% of Vincerx Pharma shares are held by insiders. Comparatively, 5.1% of Scopus BioPharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vincerx PharmaN/AN/A-$40.16M-$5.31N/A
Scopus BioPharmaN/AN/A-$11.61MN/AN/A

Vincerx Pharma has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.22, suggesting that its stock price is 122% less volatile than the broader market.

In the previous week, Vincerx Pharma's average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company Overall Sentiment
Vincerx Pharma Neutral
Scopus BioPharma Neutral

Scopus BioPharma's return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Vincerx PharmaN/A -248.33% -132.73%
Scopus BioPharma N/A N/A N/A

Summary

Vincerx Pharma and Scopus BioPharma tied by winning 3 of the 6 factors compared between the two stocks.

How does Scopus BioPharma compare to Carisma Therapeutics?

Scopus BioPharma (NASDAQ:SCPS) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Scopus BioPharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Carisma Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Carisma Therapeutics'average media sentiment score.

Company Overall Sentiment
Scopus BioPharma Neutral
Carisma Therapeutics Neutral

44.3% of Carisma Therapeutics shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by company insiders. Comparatively, 6.9% of Carisma Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Scopus BioPharma has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%.

Company Net Margins Return on Equity Return on Assets
Scopus BioPharmaN/A N/A N/A
Carisma Therapeutics -254.28%N/A -192.17%

Scopus BioPharma has a beta of -0.22, indicating that its stock price is 122% less volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of -9.02, indicating that its stock price is 1,002% less volatile than the broader market.

Scopus BioPharma has higher earnings, but lower revenue than Carisma Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scopus BioPharmaN/AN/A-$11.61MN/AN/A
Carisma Therapeutics$10.77M0.00-$60.48M$0.730.00

Summary

Scopus BioPharma and Carisma Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

How does Scopus BioPharma compare to Virpax Pharmaceuticals?

Virpax Pharmaceuticals (NASDAQ:VRPX) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company Overall Sentiment
Virpax Pharmaceuticals Neutral
Scopus BioPharma Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virpax PharmaceuticalsN/AN/A-$15.19M-$123.25N/A
Scopus BioPharmaN/AN/A-$11.61MN/AN/A

32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. 3.7% of Virpax Pharmaceuticals shares are owned by company insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Scopus BioPharma's return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Virpax PharmaceuticalsN/A -1,554.34% -338.29%
Scopus BioPharma N/A N/A N/A

Virpax Pharmaceuticals has a beta of -16.55, indicating that its stock price is 1,755% less volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.22, indicating that its stock price is 122% less volatile than the broader market.

Summary

Scopus BioPharma beats Virpax Pharmaceuticals on 5 of the 6 factors compared between the two stocks.

How does Scopus BioPharma compare to Syros Pharmaceuticals?

Scopus BioPharma (NASDAQ:SCPS) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

Scopus BioPharma's return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Scopus BioPharmaN/A N/A N/A
Syros Pharmaceuticals N/A -3,369.56%-97.04%

91.5% of Syros Pharmaceuticals shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by company insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Scopus BioPharma has a beta of -0.22, suggesting that its stock price is 122% less volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market.

Scopus BioPharma has higher earnings, but lower revenue than Syros Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scopus BioPharmaN/AN/A-$11.61MN/AN/A
Syros Pharmaceuticals$386K0.03-$164.57M-$3.03N/A

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Scopus BioPharma Neutral
Syros Pharmaceuticals Neutral

Summary

Syros Pharmaceuticals beats Scopus BioPharma on 4 of the 7 factors compared between the two stocks.

How does Scopus BioPharma compare to Trevena?

Trevena (NASDAQ:TRVN) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

Trevena has a beta of -0.55, suggesting that its stock price is 155% less volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.22, suggesting that its stock price is 122% less volatile than the broader market.

13.6% of Trevena shares are owned by institutional investors. 2.7% of Trevena shares are owned by company insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
TrevenaN/A N/A -119.55%
Scopus BioPharma N/A N/A N/A

Scopus BioPharma has lower revenue, but higher earnings than Trevena.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$443K0.02-$40.29M-$47.04N/A
Scopus BioPharmaN/AN/A-$11.61MN/AN/A

In the previous week, Trevena had 1 more articles in the media than Scopus BioPharma. MarketBeat recorded 1 mentions for Trevena and 0 mentions for Scopus BioPharma. Trevena's average media sentiment score of 0.37 beat Scopus BioPharma's score of 0.00 indicating that Trevena is being referred to more favorably in the media.

Company Overall Sentiment
Trevena Neutral
Scopus BioPharma Neutral

Summary

Trevena and Scopus BioPharma tied by winning 4 of the 8 factors compared between the two stocks.

Get Scopus BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for SCPS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SCPS vs. The Competition

Export
MetricScopus BioPharmaPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$17K$12.50B$7.26B$13.10B
Dividend YieldN/A2.63%2.52%12.57%
P/E RatioN/A792.39274.6925.75
Price / SalesN/A850.84679.2597.61
Price / CashN/A88.6477.8052.76
Price / BookN/A10.6910.526.34
Net Income-$11.61M$2.83B$3.49B$360.00M
7 Day PerformanceN/A-0.69%-1.08%-0.10%
1 Month PerformanceN/A-1.10%-3.39%-3.41%
1 Year PerformanceN/A2.10%15.08%5.46%

Scopus BioPharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SCPS
Scopus BioPharma
N/A$0.00
flat		N/A+33.3%$17KN/AN/A13
VINC
Vincerx Pharma
N/A$0.02
flat		N/A-60.8%$79KN/AN/A60
CARM
Carisma Therapeutics
0.3541 of 5 stars		$0.00
flat		N/A-99.8%$33K$10.77M0.0020
VRPX
Virpax Pharmaceuticals
N/A$0.01
+11,000.0%		N/AN/A$14KN/AN/A7
SYRS
Syros Pharmaceuticals
N/A$0.00
-96.7%		N/A+300.0%$11K$386KN/A120

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SCPS) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
They're shrinking your dollars every single month
Since 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about wh...
American Alternative | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
NASA's ISS Replacement Could Go to This Tiny Space Firm
NASA has commissioned SpaceX to decommission the $150 billion International Space Station, but the contract to...
Behind the Markets | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel